Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; small case series only; weight loss, dietary modification, and resmetirom remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for non-alcoholic fatty liver disease (NAFLD/MASLD). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for NAFLD is investigational.
- What evidence exists?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based management of NAFLD/MASLD per AASLD guidelines: weight loss 7-10 percent (most effective intervention), Mediterranean diet, reduction of fructose and alcohol intake, treatment of metabolic comorbidities (diabetes, dyslipidemia), GLP-1 receptor agonists (semaglutide, tirzepatide) for weight loss and hepatic benefit, resmetirom (newly FDA-approved for MASH with fibrosis stages F2-F3). Vitamin E in selected non-diabetics with MASH. Bariatric surgery in eligible obese patients.
- Main risks
- Bleeding from bite sites, prolonged if early cirrhosis or thrombocytopenia
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Risk in patients with advanced fibrosis or cirrhosis (variceal bleeding)
- Risk of missed hepatocellular carcinoma screening
- Substitution for weight loss, which is the proven primary intervention
- Delay of resmetirom (FDA-approved for MASH F2-F3), GLP-1, or bariatric surgery evaluation
- Risk of missed alcohol-related liver disease if alcohol intake is underreported
- Who should not consider this
- Patients with advanced fibrosis (F3) or cirrhosis (F4) with esophageal varices
- Patients with thrombocytopenia (platelets <50,000) or INR >1.5 from liver disease
- Patients with active hepatocellular carcinoma
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant patients
- Patients who have not engaged with weight loss, diet modification, or evidence-based therapy
- What to ask your clinician
- Have I had FibroScan, MRE, or biopsy to stage my fibrosis?
- Am I a candidate for resmetirom (FDA-approved for MASH with fibrosis F2-F3)?
- Have I been offered GLP-1 receptor agonists (semaglutide, tirzepatide) for weight loss?
- Am I a candidate for bariatric surgery?
- Has hepatocellular carcinoma screening been arranged (if cirrhosis)?
- What evidence specifically supports leech therapy for NAFLD?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Vomiting blood or passing black tarry stools (possible variceal bleeding)
- New abdominal swelling or jaundice (possible decompensated cirrhosis)
- New confusion or sleepiness (possible hepatic encephalopathy)
- Severe abdominal pain with fever (possible spontaneous bacterial peritonitis)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for NAFLD/MASLD.
- Anecdotal reports do NOT establish efficacy versus weight loss, resmetirom, GLP-1 receptor agonists, or bariatric surgery.
- It does NOT substitute for weight loss, which is the most effective intervention for fatty liver.
- It does NOT replace hepatocellular carcinoma screening in patients with cirrhosis.
- It does NOT mean leech application is safe in patients with advanced fibrosis or coagulopathy.
Safety cross-references
Clinical Profile
- Category
- gastrointestinal
- ICD-10
- K76.0, K75.81
- Safety tier
- high
Evidence Summary
Non-alcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease, MASLD) is managed per AASLD 2023 guidance with weight loss (>=10% for MASH reversal), Mediterranean diet, exercise, glycemic control, statin therapy when indicated, and resmetirom (FDA-approved 2024) for fibrosis F2-F3. No controlled clinical trial of leech therapy for NAFLD/MASLD has been published; use is investigational and mechanistic only, and the honest evidence grade is D. Any hepatic-decongestion or antiinflammatory rationale for application over a hepatic reflex zone is theoretical, would be confounded by concurrent lifestyle change, and cannot address fibrosis progression.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Andereya S et al. (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Cirrhosis (Child-Pugh B/C, or any decompensation)
- Esophageal varices or portal hypertension
- Coagulopathy from hepatic dysfunction
- Concurrent alcoholic or viral hepatitis
- Hepatocellular carcinoma surveillance abnormality
Related Conditions
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
External Thrombosed Hemorrhoid (Acute, <72h)
Investigational adjunct for acute external thrombosed hemorrhoids presenting within 72 hours; distinct from internal hemorrhoidal disease.
Chronic Anal Fissure (>8 Weeks)
Investigational adjunct for chronic anal fissure refractory to medical therapy; very limited case-report evidence; surgical sphincterotomy remains gold standard.
Hepatic Portal Congestion (Non-Cirrhotic, Investigational)
Highly investigational adjunct for non-cirrhotic hepatic congestion; case reports only; cirrhosis and portal hypertension are absolute exclusions.